Expanding the Phenotype: Four New Cases and Hope for Treatment in Bachmann-Bupp Syndrome

    Elizabeth VanSickle, Julianne Michael, André S. Bachmann, Surender Rajasekaran, Jeremy W. Prokop, Ruben Kuzniecky, Floris C. Hofstede, Katharina Steindl, Anita Rauch, Mark Lipson, Caleb Bupp
    TLDR Four new cases of Bachmann-Bupp syndrome suggest potential for targeted treatment.
    Bachmann-Bupp syndrome (BABS) is a rare condition caused by gain-of-function variants in the ODC1 gene, leading to developmental delay, macrocephaly, macrosomia, and non-congenital alopecia. The diagnosis of four new patients expanded the known phenotype to include late-onset seizures, observed in a 23-year-old patient. Neuroimaging abnormalities remained inconsistent, possibly due to unknown effects of ODC/polyamine dysregulation on brain development. Variants clustered around elevated ODC protein and enzyme activity, suggesting a universal biochemical mechanism. Recommendations for medical management and potential targeted molecular or metabolic testing were proposed. The natural history of BABS might evolve with DFMO therapy, prompting further research.
    Discuss this study in the Community →

    Cited in this study

    2 / 2 results